Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with Hig... (s why this test is now used in many medi...)

HOME >> MEDICINE >> TECHNOLOGY

Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL

Date:12/9/2008

s why this test is now used in many medical centers.

Additional abstracts examining Campath in high-risk CLL patients presented at ASH showed comparable results.

About Campath

Campath was the first monoclonal antibody approved by the United States Food and Drug Administration (FDA) for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). In September 2007, the FDA approved a supplemental Biologics License Application (sBLA) for Campath and granted regular approval for Campath as a single-agent for the treatment of B-CLL. Campath was initially approved in 2001 under accelerated approval regulations for the treatment of B-CLL in patients who have been treated with alkylating agents and who have failed fludarabine therapy. Campath was developed by Genzyme Corporation. Campath is marketed in the U.S. by Bayer HealthCare Pharmaceuticals Inc., as Campath, and outside the United States as MabCampath(R).

For more information about Campath, including full prescribing information, call 1-888-84-BAYER (1-888-842-2937) or visit http://www.campath.com.

Important Safety Information

WARNING: CYTOPENIAS, INFUSION REACTIONS, AND INFECTIONS

Cytopenias: Serious, including fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving Campath. Single doses of Campath greater than 30mg or cumulative doses greater than 90mg per week increase the incidence of pancytopenia.
Infusion Reactions: Campath administration can result in serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold Campath for Grade 3 or 4 infusion reactions. Gradually escalate Campath to the recommended dose at the initiation of t
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
3. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
4. Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
5. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
6. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
7. Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
8. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
9. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
10. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
11. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial

Post Your Comments:

(Date:12/14/2009)... Dec. 14 Cardium Therapeutics (NYSE Amex: ... 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the Treatment ... Healing: Science and Industry Conference held December 10-13, ... The conference is attended by top industry leaders ... wound healing. Dr. Barbara K. Sosnowski, Cardium,s ...

(Date:12/14/2009)... SKIPPACK, Pa., Dec. 14 At GeoInvesting.com, we ... ) for some time now. Our largest hang up ... Although the Company,s fiscal June 2010 net income guidance ... fiscal 2009 reported net income of $7.9 million, the ... term EPS growth scenario, which depends upon the share ...

(Date:12/14/2009)... HELSINKI, Dec. 14 Cancer patients in ... with the introduction of RapidArc® radiotherapy technology from ... at the only private radiotherapy clinic in the ... are using this fast and precise form of ... and cancers of the abdomen and prostate. ,, ...

Breaking Medicine Technology:Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 2 Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 3 Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 4 GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms 2 Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 2 Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments 3 Time to Turn the Town Pink 57587 1 Time to Turn the Town Pink 57587 2 Dey L P Settles State of Utah Pricing Litigation 57583 1 Dey L P Settles State of Utah Pricing Litigation 57583 2 The Lustgarten Foundation Expresses Condolences as Pancreatic Cancer Claims Life of Myles Brand 57580 1

[0] Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development [0] GeoInvesting.com Offers Insight Into Two Growing Chinese Pharmaceutical Firms [0] Cancer Patients in Finland Gain Access to Advanced RapidArc Radiotherapy Treatments

... - ORENCIA is a First-in-Class Biologic Treatment Option Now Available ... Use in Pediatric Patients with ... Company (NYSE: BMY ) today announced that the U.S. ... signs,and symptoms in pediatric patients six years and older with ...

... Inc. (Nasdaq: ARNA ) announced today that ... of APD125 in patients with primary,insomnia. APD125 is ... the,potential to reduce insomnia symptoms and improve sleep ... APD125 is a double-blind, randomized, placebo-,controlled subjective study ...

U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia

(Date:12/15/2009)... bill Medicare for consultations how will they get paid for ... to understand terms. , ... Washington, ... Medicare will eliminate consultation codes. These codes are what ... is seen for a medical consultation, whether in a provider’s ...

(Date:12/15/2009)... America,s premier manufacturer of Spa, Massage, and Medical tables announces ... an adjustable breast comfort system to ease pressure felt while ... ... New Freedom, Pennsylvania (PRWEB) December 15, 2009 -- OAKWORKS®, ... equipment, today announced the launch of the Utopian Massage Table ...

(Date:12/15/2009)... 15 issue of the Journal of Clinical Sleep ... the risk for developing obstructive sleep apnea (OSA) in ... Results indicate that the risk of OSA among Caucasian ... fold with each standard-deviation increase in body mass index ... significantly increase with increasing BMI among younger children. ...

(Date:12/14/2009)... and synthetic red-blood-cell-like particles carry oxygen, drugs, and more… ... ... Scientists at UC Santa Barbara, in collaboration with scientists at ... the characteristics and key functions of natural red blood cells, ... , , , , ,The primary function of natural red ...

(Date:12/14/2009)... LOVELAND, Colo., Dec. 14 Heska ... the "Company"), a leading provider of veterinary ... first customer installation of the Company,s new ... 7000"). ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGO ) ,, ... the fastest multi-patient clinical chemistry analyzer available ...

Breaking Medicine News(10 mins):Health News:Medicare Eliminates Consultation Codes for Doctors 2 Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 2 Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 3 Health News:Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table 4 Health News:Obesity increases the risk for obstructive sleep apnea in adolescents, but not in younger children 2 Health News:Synthetic Red Blood Cells Developed 2 Health News:Synthetic Red Blood Cells Developed 3 Health News:Heska Announces Installation of New Chemistry Analyzer 2 Health News:Heska Announces Installation of New Chemistry Analyzer 3

[0] Medicare Eliminates Consultation Codes for Doctors [0] Wellness Equipment Manufacturer Announces Revolutionary New Adjustable Breast Comfort System Available on Utopian Portable Massage Table [1] Obesity increases the risk for obstructive sleep apnea in adolescents, but not in younger children [0] Synthetic Red Blood Cells Developed [0] Heska Announces Installation of New Chemistry Analyzer

... displacement in the ivyleaf morning glory" , Robin ... , How do we know that interactions between ... abundant evidence to suggest that plant-pollinator interactions influence ... direct evidence that interactions between plant species shape ...

... INDIANAPOLIS, Jan. 4 Eli Lilly and Company,(NYSE: LLY ... and,full year of 2007 on Tuesday, January 29, 2008. Lilly ... investment community and media to,further detail the company,s financial performance., ... to 10:00 a.m. EST.,Investors, media and the general public can ...

... HARRISBURG, Pa., Jan. 4 With the cut of ... some 400 jobs in,Northumberland County and mark the acquisition ... PRWT Services Inc. took over the operation of ... Danville, on Jan. 1. The facility will be,known as ...

... as well with more cost-effective conventional film screenings, study ... results from a landmark trial released in 2005 concluded ... cancers than conventional film mammography was. , But a ... of Internal Medicine , concludes that digital mammography is ...

... get serious about ... health, once and for all, NEW ... and stroke are the nation,s No. 1 and No. 3,killers, claiming ... obese., (Photo: http://www.newscom.com/cgi-bin/prnh/20080104/LAF034 ), World-renowned entertainer Donny Osmond ...

... for 29 categories of awards in the 2007 Association ... Best Monthly Professional Society Magazine as well as the ... winners will be honored at the Salute to Association ... 1996, JBS is the official publication of the Society ...

January American Naturalist highlights Lilly Sets Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results Announcement Governor Rendell Lauds 'Rebirth' of Drug Manufacturing Plant in Danville Area Not All Women Need Digital Mammograms Donny Osmond, American Heart Association Team Up to Get Americans Walking The Journal of Biomolecular Screening garners Association TRENDS Bronze Award

...

Tip is bent towards port for downward irrigation. 25G x 7/8in (.50 x 16mm)...

Medicine Products:

J Hydrodissector - Newman Hydrodissector - Daya Hydrodissector - Pearce Blunt Tip Cystotome - Reverse

Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with Hig...(s why this test is now used in many medi...),Health